Study Evaluating Pamrevlumab for Idiopathic Pulmonary Fibrosis Misses Endpoints
A phase 3 study evaluating the efficacy and safety of pamrevlumab in patients with idiopathic pulmonary fibrosis did not meet its primary endpoint.
Source: empr.com
Page 2 - Markd Eisner News Today : Breaking News, Live Updates & Top Stories | Vimarsana
Stay updated with breaking news from Markd Eisner. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Top News In Markd Eisner Today - Breaking & Trending Today
Chinese Phase 3 Trial of Roxadustat in Non-Myeloid Malignancies Meets Primary End Point
Roxadustat proved to be noninferior to recombinant erythropoietin alfa with regard to change in hemoglobin level from baseline to an average level during weeks 9 to 13 in patients receiving concurrent chemotherapy for non-myeloid malignancies in China, meeting the primary end point of an ongoing phase 3 trial.
Source: onclive.com